Research
GLP-1 Antagonist Shows Clinically Meaningful Results in Post-Bariatric Hypoglycemia
The Brief
- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycaemic events after bariatric surgery in the phase III LUCIDITY trial.
- The reported baseline mean was 2.39 hypoglycaemic events per period; the source text is cut off before the period and the post-treatment figures are not given.
- The results were presented at ObesityWeek in National Harbor, Md., and described by MedPage Today as clinically meaningful.
Why it matters
Post-bariatric hypoglycaemia is a recurring complication with few targeted treatments, so a phase III result with a significant reduction in events is relevant to clinicians and researchers in obesity and metabolic medicine. The drug is still investigational and not approved.
Who’s affected
- clinicians and researchers treating patients after bariatric surgery
- patients who have had bariatric surgery and experience hypoglycaemia
- #glp-1
- #bariatric surgery
- #hypoglycaemia
- #clinical trial
- #obesity
(MedPage Today) -- NATIONAL HARBOR, Md. -- An investigational first-in-class GLP-1 receptor antagonist significantly reduced hypoglycemic events after bariatric surgery in the phase III LUCIDITY trial. From a baseline mean of 2.39 events per...